| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1486 | Cm-352 | Novel Matrix Metalloproteinase Inhibitor As a Potent Antihemorrhagic Agent |
|
| DCC1487 | Cm-407 | First-in-class dual PDE5 and HDAC6-selective inhibitor |
|
| DCC1488 | Cm-444 | Novel Epigenetic Inhibitor Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma |
|
| DCC1489 | cm-9-78 | Novel inhibitor of |
|
| DCC1490 | Cmap-7 | Novel Hedgehog pathway inhibitor, revealing the receptor GPR39 |
|
| DCC1491 | Cmb4563 | Novel Potent and Specific Target Of Rapamycin Complex 2 (TORC2) Inhibitor |
|
| DCC1492 | Cmcofx1 | Novel ultrapotent and selective inhibitor of of human β-Factor XIIa |
|
| DCC1493 | Cmd178 Tfa Salt | Novel peptide STAT5 inhibitor, blocking IL-2/sIL-2Rα signaling and inhibiting T reg cell development |
|
| DCC1494 | Cm-ff-h | Novel SARS-CoV Mpro inhibitor which has its P1-phenylalanine residue bound to the relatively hydrophilic S1 pocket of the enzyme and yet exhibits a high inhibitory activity against SARS-CoV Mpro, with Ki = 2.24 ± 0.58 μM |
|
| DCC1495 | Cmi-392 | Potent dual 5-lipoxygenase (5-LOX) inhibitor and platelet-activating factor (PAF) receptor antagonist |
|
| DCC1496 | cmpd 339509 | Inhibitor of DprE1, an epimerase required for cell wall biosynthesis |
|
| DCC1497 | Cmpd-15pa | Novel allosteric modulator of the β2 adrenergic receptor (β2AR), binding to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8 |
|
| DCC1498 | Cmpi Hydrochloride | Selective and potent potentiator of nAChRs containing an α4 |
|
| DCC1499 | Cmx020 | Novel TRPV1 modulator, also modulating both CB1 and CB2 receptors |
|
| DCC1500 | Cmx521 | Novel Inhibitor for RNA-Dependent RNA Polymerase of Norovirus |
|
| DCC1501 | Cn14_17 | Novel Potent Inhibitor of the HIV-1 Nucleocapsid Protein |
|
| DCC1502 | Cn-716 | Novel Zika virus (ZIKV) NS2B-NS3pro protease inhibitor |
|
| DCC1503 | cn-chalc4 | Novel blocker of binding of CXCL12 to CXCR4 |
|
| DCC1504 | Cng-10300 | Novel partial blocker of GluK1, with GluK2 being unaffected |
|
| DCC1505 | Cni103 | Novel potent and selective blocker of the calcineurin-NFAT interaction (KD=16nM), preventing acute lung injury, being a promising novel treatment for ARDS and other inflammatory diseases |
|
| DCC1506 | Cns1261 | N-methyl-D-aspartate (NMDA) receptor ligand, selectivity targeting the intrachannel PCP/ketamine/MK-801 site of NMDA receptor |
|
| DCC1507 | Cns-5161 | Novel and selective noncompetitive antagonist of the NMDA |
|
| DCC1508 | Cny-07 | Novel potent RIPK1/necroptosis ligand, penetrate the blood-brain barrier |
|
| DCC1509 | Cobimetinib Hemifumarate | Novel inhibitor of mitogen-activated protein kinase (MAPK) |
|
| DCC1511 | Coibamide A | Natural lariat depsipeptide, inhibiting VEGFA/VEGFR2 expression and suppressing tumor growth in glioblastoma xenografts, targeting Sec61 to prevent biogenesis of secretory and membrane proteins |
|
| DCC1512 | Col049 | Novel potent and selective inhibitor of the interaction between Hsp47 and collagen |
|
| DCC1513 | Col050 | Novel potent and selective inhibitor of the interaction between Hsp47 and collagen |
|
| DCC1514 | Col051 | Novel potent and selective inhibitor of the interaction between Hsp47 and collagen |
|
| DCC1515 | Colletochlorin B | Natural differentiation inducer of human promyelocytic leukemia cells |
|
| DCC1516 | Combretastatin | Inhibitor of tubulin polymerization, preventing cancer cells from producing microtubules |
|
